IP finance

"Where money issues meet IP rights". This weblog looks at financial issues for intellectual property rights: securitisation and collateral, IP valuation for acquisition and balance sheet purposes, tax and R&D breaks, film and product finance, calculating quantum of damages--anything that happens where IP meets money.

Showing posts with label biopharmaceutical pricing. Show all posts
Showing posts with label biopharmaceutical pricing. Show all posts
Monday, 8 August 2022

Proposed U.S. Inflation Reduction Act Takes on (some) Drug Pricing Issues in United States

›
U.S. Senator Joe Manchin released a press release concerning the U.S. Senate’s passage of the Inflation Reduction Act of 2022.  Importantly...
Wednesday, 3 November 2021

U.S. FDA Sends Letter to Push USPTO Concerning Drug Patents and Access

›
The U.S. Federal Food and Drug Administration (FDA) recently sent a letter to the U.S. Patent and Trademark Office concerning the FDA’s conc...
Wednesday, 30 May 2018

FDA Attempts to Shame Pharmacuetical and Biotechnology Companies

›
The U.S. Federal Drug Administration (FDA) recently decided to try to “shame” some pharmaceutical and biotechnology companies for failin...
Monday, 26 February 2018

Trump White House Releases Biopharmaceutical Pricing Reform White Paper

›
The White House Council of Economic Advisers recently released a report titled, “Reforming Biopharmaceutical Pricing at Home and Abroad....
›
Home
View web version
Powered by Blogger.